PS
TXMD icon

Principal Securities’s TherapeuticsMD TXMD Stock Holding History

Principal Securities’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-126
Closed -$209 – 3630
2024
Q3 		$209 Hold
126
– – ﹤0.01% 3355
2024
Q2 		$203 Hold
126
– – ﹤0.01% 3310
2024
Q1 		$289 Hold
126
– – ﹤0.01% 3208
2023
Q4 		$284 Buy
+126
New +$304 ﹤0.01% 3117

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Principal Securities's TXMD Position: Q4 2024 in Review

Principal Securities sold out of TherapeuticsMD (TXMD) in Q4 2024, closing a stake of 126 shares — an estimated $209 sold.

Principal Securities first reported a position in TXMD in Q4 2023 and held it in 4 quarters. The position peaked at $289 in Q1 2024. 41 funds tracked by Wall St. Rank hold TXMD as of Q4 2024.

  • Principal Securities reported no remaining TherapeuticsMD position as of Q4 2024 after selling out during the quarter.
  • Principal Securities sold 126 TherapeuticsMD shares in Q4 2024, an estimated $209.
  • Principal Securities first reported a position in TherapeuticsMD in Q4 2023 and held it in 4 quarters.
  • Principal Securities's TherapeuticsMD position peaked at $289 in Q1 2024.
  • 41 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2024.

Based on Principal Securities's 13F filing for Q4 2024, filed 30 Jan 2025.